论文部分内容阅读
目的评价科比特联合布地奈德雾化吸入治疗慢性阻塞性肺疾病(COPD)急性发作的疗效。方法选择38例慢性阻塞性肺疾病急性加重期(AECOPD)患者,随机分为观察组和对照组,对照组18例在予以氧疗、解痉、祛痰等常规治疗的基础上,给可比特雾化吸入,2ml/次,2次/d,观察组20例在常规治疗的基础上给予可比特联合布地奈德氧气驱动雾化吸入,2次/d。结果治疗7d后,观察组总有效率90%(18/20)对照组总有效率72.2%(13/18)。观察组优于对照组(P<0.05)。结论可比特联合布地奈德雾化吸入治疗AECOPD效果显著,无明显副作用,效果肯定。
Objective To evaluate the efficacy of corbovirum combined with budesonide in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods Thirty-eight patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) were randomly divided into observation group and control group. In the control group, 18 patients were treated with conventional therapy such as oxygen therapy, antispasmodic and expectorant treatment, Inhalation inhalation, 2ml / time, 2 times / d, the observation group of 20 patients on the basis of routine treatment given budesonide budesonide aerosol inhalation, 2 times / d. Results After 7 days of treatment, the total effective rate was 90% (18/20) in the observation group and 72.2% (13/18) in the control group. The observation group was better than the control group (P <0.05). Conclusion The combination of budesonide and budesonide inhalation is effective in treating AECOPD with no obvious side effects and the effect is definite.